Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients
The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an elevation of liver enzymes, hyperglycaemia [53], new onset of diabetes mellitus type 2 [54] and proteinuria.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [53]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Levitan, E. B., Song, Y., Ford, E. S., & Liu, S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2147 · Cited by 668
Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., & Yada, T. (2006) · Diabetologia · doi:10.1007/s00125-006-0269-5 · Cited by 293
Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose.
Santaguida, P. L., Balion, C. M., Hunt, D., Morrison, K. M., Gerstein, H. C., Raina, P. S., Booker, L., & Yazdi, H. (2005) · PubMed · Cited by 242
Yada, T., Nakata, M., Shiraishi, T., & Kakei, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702397 · Cited by 229
Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes
Chamberlain, L. H. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03007-1 · Cited by 135
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 102
Statins: Beneficial or Adverse for Glucose Metabolism
Sasaki, J., Iwashita, M., & Kono, S. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.123 · Cited by 82
Blood Glucose and Coronary Artery Disease in Nondiabetic Patients
Nielson, C., Lange, T., & Hadjokas, N. (2006) · Diabetes Care · doi:10.2337/dc05-1902 · Cited by 60
Research works printed but not linked: 7
- Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
- Collins R, 2003, Lancet, 361, 2005
- Colhoun HM, 2004, Lancet, 9435, 685
- Sabatine MS, 2004, Circulation, 110, S834
- Nakata M, 2006, Diabetologia, 49, 1881
- Sever PS, 2003, Lancet, 361, 1149
- Levitan EB, Arch Intern Med, 2147
Cited by
Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500
“Nutr Metab Cardiovasc Dis (2010) 20(5):366–75.”
BackgroundPharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Cederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., & Laakso, M. (2015) · Diabetologia · doi:10.1007/s00125-015-3528-5 · Cited by 316
Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism
Caparrós-Martín, J. A., Lareu, R. R., Ramsay, J. P., Peplies, J., Reen, F. J., Headlam, H. A., Ward, N. C., Croft, K. D., Newsholme, P., Hughes, J. D., et al. (2017) · Microbiome · doi:10.1186/s40168-017-0312-4 · Cited by 212
Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170
Metadata
- Authors
- Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D., Sachdeva, R., Kesan, S. H., & Mehta, J. L.
- Affiliations
- Division of Cardiovascular Medicine, Little Rock
- Central Arkansas Veterans Healthcare System (US)
- University of Arkansas for Medical Sciences (US)
- Venue
- Journal of Investigative Medicine
- Publisher
- SAGE Publications
- Published
- 2009-03
- Volume
- 57
- Issue
- 3
- Pages
- 495-499
- ISSN
- 1081-5589 (ISSN-L)
- 1708-8267
- OpenAlex
- W121422619
- Cited by
- 126
- References
- 20
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 11 · 2014: 12 · 2013: 12 · 2012: 15
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Investigative Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, fasting blood glucose, hyperglycemia, diabetes mellitus, glucose metabolism, veterans, insulin secretion, adverse drug reactions
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Fasting, Food Deprivation, Humans, Hypertension, Male, Middle Aged, United States, Veterans, Databases, Factual, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Complications, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.